Highest-materiality recent filing
AdaptHealth Q1 net loss widens to $16M, COO replaced; raises revenue guidance
Net revenue $819.8M (+5.4% YoY); net loss $16.0M vs $7.2M loss in Q1 2025.
AdaptHealth closes $1.1B credit facility with reduced pricing and extended maturity to 2031
New facility: $325M term loan, $325M delayed draw term loan, $450M revolver (previously $300M).
Full-year 2025 net loss $70.8M vs net income $90.4M in 2024; includes $128M goodwill impairment.
Net income $24.5M vs $22.9M; YTD free cash flow $140.1M vs $162.7M.
Partnership with a large California-based integrated delivery network; exclusive provider of HME for its 10M+ members.
AdaptHealth Q2 2025 revenue $800.4M, net income $14.7M; lowers FY adjusted EBITDA guidance
Net revenue $800.4M, down 0.7% YoY; net income $14.7M vs $19.4M in prior year.
AdaptHealth closes infusion asset sale, reduces debt by $65M, updates FY2025 guidance
Closed disposition of certain infusion assets in Wellness at Home segment; assets had ~$52M annual revenue and ~$5M annual Adjusted EBITDA.
AdaptHealth Q1 revenue down 1.8% to $778M; net loss widens; guides FY25 lower on asset sales
Net revenue $777.9M (-1.8% YoY); net loss $7.2M vs $2.1M loss prior year.
AdaptHealth reports FY2024 net income of $90.4M vs prior year loss; revenue up 1.9%
FY2024 net revenue $3.261B (+1.9% YoY); net income attributable $90.4M vs net loss $678.9M.
AdaptHealth Q3 net income $22.9M, revenue $805.9M; raises free cash flow guidance
Net income attributable to AdaptHealth of $22.9M vs net loss of $454.1M in Q3 2023.
AdaptHealth corrects private warrant expiry to Nov 8, 2024 from previously reported Nov 20
Notice to private placement warrant holders confirms expiration date is November 8, 2024 at 5:00 PM ET.
New facility: $650M Term Loan A (fully funded) + $300M Revolver, replacing $450M revolver and existing term loan due Jan 2026.
AdaptHealth Q2 revenue $806M (+1.6% YoY); net income $19.4M; narrows guidance
Net revenue $806.0M vs $793.3M YoY; net income $19.4M (+39%); adjusted EBITDA $165.3M (-3.3%).
AdaptHealth President Josh Parnes to resign, Dale Wolf named Board Chair
Josh Parnes steps down as President effective Aug 31, 2024, and from Board Dec 31, 2024.
the appointment of Daniel McFadden as Chief Operating Officer of the Company, effective as of May 4, 2026
Also on May 4, 2026, the Company appointed Daniel McFadden, the Company’s current Chief Business Systems Officer, as the Company’s Chief Operating Officer.
On May 4, 2026, the Company terminated the employment of Toby Scott Barnhart, the Company’s Chief Operating Officer.
On October 16, 2024, following the recommendation of the nominating and governance committee of AdaptHealth Corp. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Diana L. Nole, age 59, to the Board, effective October 16, 2024.
Toby Scott Barnhart, age 56, has been appointed to serve as the Chief Operating Officer of the Company, effective as of September 23, 2024
On August 13, 2024, AdaptHealth Corp. (the “Company”) informed Shaw Rietkerk of its intention to transition him to a new position as the Company’s Chief Business Officer, by the end of September, 2024, following which Mr. Rietkerk will no longer serve as the Company’s Chief Operating Officer.
the Company and Joshua Parnes, the Company’s President, mutually agreed that Mr. Parnes will resign from all positions that he holds with the Company and its affiliates, effective as of 11:59 p.m. E.D.T. on August 31, 2024
Max materiality 0.75 · Median 0.62 · Most common event earnings